A French single-center experience on allogeneic stem cell transplant cryopreservation during severe acute respiratory syndrome coronavirus 2 pandemic.

Fiche publication

Date publication

avril 2023

Journal

Cytotherapy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle , Pr RUBIO Marie Thérèse , Pr THILLY Nathalie , Pr DECOT Véronique , Dr D'AVENI-PINEY Maud , Dr POCHON Cécile , Dr GAUTHIER Michaël

Tous les auteurs :
Laroye C, Thilly N, Gauthier M, Luc A, Latger-Cannard V, Eschwege V, Bensoussan D, Pochon C, Campidelli A, Rubio MT, D'Aveni M, Decot V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37178096

Résumé

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for chemo-resistant hematological malignancies. Because of transport restriction imposed by the coronavirus disease 2019 pandemic, regulatory bodies and societies recommended graft cryopreservation before recipient conditioning. However, the freezing and thawing processes, including washing steps, might impair CD34+ cell recovery and viability, thereby impacting the recipient engraftment. Over 1 year (between March 2020 and May 2021), we aimed to analyze the results of frozen/thawed peripheral blood stem cell allografts in terms of stem cell quality and clinical outcomes.